JP2011507856A - 整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用 - Google Patents

Info

Publication number

JP2011507856A

JP2011507856A JP2010539512A JP2010539512A JP2011507856A JP 2011507856 A JP2011507856 A JP 2011507856A JP 2010539512 A JP2010539512 A JP 2010539512A JP 2010539512 A JP2010539512 A JP 2010539512A JP 2011507856 A JP2011507856 A JP 2011507856A

Authority

JP

Japan

Prior art keywords

connexin

composition

agent

polynucleotide

agents

Prior art date

2007-12-21

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 230000000399 orthopedic effect Effects 0.000 title claims abstract description 66
• 102000040430 polynucleotide Human genes 0.000 title claims description 171
• 108091033319 polynucleotide Proteins 0.000 title claims description 171
• 239000002157 polynucleotide Substances 0.000 title claims description 171
• 108090000765 processed proteins & peptides Proteins 0.000 title claims description 111
• 238000011282 treatment Methods 0.000 title abstract description 47
• 102000004196 processed proteins & peptides Human genes 0.000 title description 51
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 266
• 239000000203 mixture Substances 0.000 claims abstract description 223
• 238000000034 method Methods 0.000 claims abstract description 170
• 230000029663 wound healing Effects 0.000 claims abstract description 105
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 66
• 201000010099 disease Diseases 0.000 claims abstract description 35
• 150000001875 compounds Chemical class 0.000 claims abstract description 30
• 208000035475 disorder Diseases 0.000 claims abstract description 30
• 230000002159 abnormal effect Effects 0.000 claims abstract description 20
• 230000009772 tissue formation Effects 0.000 claims abstract description 18
• 208000002193 Pain Diseases 0.000 claims abstract description 16
• 230000036407 pain Effects 0.000 claims abstract description 16
• 238000001356 surgical procedure Methods 0.000 claims description 86
• 239000003814 drug Substances 0.000 claims description 71
• 208000027418 Wounds and injury Diseases 0.000 claims description 68
• 230000000692 anti-sense effect Effects 0.000 claims description 59
• 229940124597 therapeutic agent Drugs 0.000 claims description 46
• 108010069241 Connexin 43 Proteins 0.000 claims description 34
• 102000001045 Connexin 43 Human genes 0.000 claims description 34
• 229940044684 anti-microtubule agent Drugs 0.000 claims description 31
• 239000012634 fragment Substances 0.000 claims description 29
• 230000014509 gene expression Effects 0.000 claims description 27
• 208000014674 injury Diseases 0.000 claims description 25
• 238000011084 recovery Methods 0.000 claims description 25
• 108091034117 Oligonucleotide Proteins 0.000 claims description 22
• 230000027455 binding Effects 0.000 claims description 20
• 238000009739 binding Methods 0.000 claims description 20
• 239000000816 peptidomimetic Substances 0.000 claims description 20
• 230000006378 damage Effects 0.000 claims description 18
• 208000024891 symptom Diseases 0.000 claims description 17
• 206010023201 Joint contracture Diseases 0.000 claims description 13
• 108020004459 Small interfering RNA Proteins 0.000 claims description 10
• 108091030071 RNAI Proteins 0.000 claims description 9
• 230000001976 improved effect Effects 0.000 claims description 9
• 230000004899 motility Effects 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 230000008568 cell cell communication Effects 0.000 claims description 7
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
• 230000009368 gene silencing by RNA Effects 0.000 claims description 6
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 5
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 5
• 239000000427 antigen Substances 0.000 claims 2
• 102000036639 antigens Human genes 0.000 claims 2
• 108091007433 antigens Proteins 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 abstract description 24
• 239000003085 diluting agent Substances 0.000 abstract description 21
• 206010061218 Inflammation Diseases 0.000 abstract description 13
• 230000004054 inflammatory process Effects 0.000 abstract description 13
• 230000037390 scarring Effects 0.000 abstract description 9
• 230000001737 promoting effect Effects 0.000 abstract description 7
• 208000002847 Surgical Wound Diseases 0.000 abstract description 2
• 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
• 108050001175 Connexin Proteins 0.000 description 180
• 102000010970 Connexin Human genes 0.000 description 176
• 238000009472 formulation Methods 0.000 description 78
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 59
• 206010052428 Wound Diseases 0.000 description 50
• 150000001413 amino acids Chemical class 0.000 description 46
• 210000003976 gap junction Anatomy 0.000 description 42
• 230000037396 body weight Effects 0.000 description 41
• 239000008194 pharmaceutical composition Substances 0.000 description 38
• 239000000499 gel Substances 0.000 description 36
• 108020004999 messenger RNA Proteins 0.000 description 27
• 230000000694 effects Effects 0.000 description 26
• 210000001519 tissue Anatomy 0.000 description 26
• 239000003112 inhibitor Substances 0.000 description 25
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
• 210000004027 cell Anatomy 0.000 description 24
• 210000003127 knee Anatomy 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 22
• 125000003275 alpha amino acid group Chemical group 0.000 description 22
• 230000008439 repair process Effects 0.000 description 22
• 238000002347 injection Methods 0.000 description 20
• 239000007924 injection Substances 0.000 description 20
• 238000006467 substitution reaction Methods 0.000 description 20
• 239000000463 material Substances 0.000 description 19
• 210000002832 shoulder Anatomy 0.000 description 19
• 239000003102 growth factor Substances 0.000 description 18
• 229920001184 polypeptide Polymers 0.000 description 18
• 239000000047 product Substances 0.000 description 18
• 210000002435 tendon Anatomy 0.000 description 18
• 206010017076 Fracture Diseases 0.000 description 17
• 229940079593 drug Drugs 0.000 description 17
• 239000000853 adhesive Substances 0.000 description 16
• -1 for example Substances 0.000 description 16
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 16
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 16
• 102000004127 Cytokines Human genes 0.000 description 15
• 108090000695 Cytokines Proteins 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 15
• 230000000699 topical effect Effects 0.000 description 15
• 235000018102 proteins Nutrition 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 102000014914 Carrier Proteins Human genes 0.000 description 13
• 230000001070 adhesive effect Effects 0.000 description 13
• 108091008324 binding proteins Proteins 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• 239000000017 hydrogel Substances 0.000 description 13
• 239000010410 layer Substances 0.000 description 13
• 239000002773 nucleotide Substances 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 238000002360 preparation method Methods 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 206010003246 arthritis Diseases 0.000 description 12
• 210000001624 hip Anatomy 0.000 description 12
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
• 231100000241 scar Toxicity 0.000 description 12
• 208000010392 Bone Fractures Diseases 0.000 description 11
• 210000000988 bone and bone Anatomy 0.000 description 11
• 239000006260 foam Substances 0.000 description 11
• 239000011159 matrix material Substances 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 108020004414 DNA Proteins 0.000 description 10
• 102100039290 Gap junction gamma-1 protein Human genes 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 108010015426 connexin 45 Proteins 0.000 description 10
• 229920000642 polymer Polymers 0.000 description 10
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• 239000002953 phosphate buffered saline Substances 0.000 description 9
• 210000003491 skin Anatomy 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 108091026890 Coding region Proteins 0.000 description 8
• 102000008186 Collagen Human genes 0.000 description 8
• 108010035532 Collagen Proteins 0.000 description 8
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 8
• 102100039417 Gap junction beta-5 protein Human genes 0.000 description 8
• 238000011882 arthroplasty Methods 0.000 description 8
• 229920001436 collagen Polymers 0.000 description 8
• 108010021208 connexin 31.1 Proteins 0.000 description 8
• 239000006071 cream Substances 0.000 description 8
• 210000001723 extracellular space Anatomy 0.000 description 8
• 210000003811 finger Anatomy 0.000 description 8
• 230000033001 locomotion Effects 0.000 description 8
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 8
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
• 229960002216 methylparaben Drugs 0.000 description 8
• 239000002674 ointment Substances 0.000 description 8
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 8
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 8
• 229960003415 propylparaben Drugs 0.000 description 8
• 238000013268 sustained release Methods 0.000 description 8
• 239000012730 sustained-release form Substances 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
• 108010069156 Connexin 26 Proteins 0.000 description 7
• 102000055974 Connexin 26 Human genes 0.000 description 7
• 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 7
• 239000002250 absorbent Substances 0.000 description 7
• 230000002745 absorbent Effects 0.000 description 7
• 235000010443 alginic acid Nutrition 0.000 description 7
• 229920000615 alginic acid Polymers 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 108010014510 connexin 40 Proteins 0.000 description 7
• 210000000805 cytoplasm Anatomy 0.000 description 7
• 230000003111 delayed effect Effects 0.000 description 7
• 210000001513 elbow Anatomy 0.000 description 7
• 230000035876 healing Effects 0.000 description 7
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 7
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 7
• 210000001503 joint Anatomy 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 230000004048 modification Effects 0.000 description 7
• 238000012986 modification Methods 0.000 description 7
• 239000008363 phosphate buffer Substances 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 230000008733 trauma Effects 0.000 description 7
• 230000003966 vascular damage Effects 0.000 description 7
• 208000032544 Cicatrix Diseases 0.000 description 6
• 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 6
• 102100037260 Gap junction beta-1 protein Human genes 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 206010023204 Joint dislocation Diseases 0.000 description 6
• 206010062575 Muscle contracture Diseases 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 239000002131 composite material Substances 0.000 description 6
• 108010015416 connexin 32 Proteins 0.000 description 6
• 208000006111 contracture Diseases 0.000 description 6
• 230000003828 downregulation Effects 0.000 description 6
• 239000000839 emulsion Substances 0.000 description 6
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
• 239000007943 implant Substances 0.000 description 6
• 238000002684 laminectomy Methods 0.000 description 6
• 210000002414 leg Anatomy 0.000 description 6
• 239000003607 modifier Substances 0.000 description 6
• 210000003205 muscle Anatomy 0.000 description 6
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
• 230000036961 partial effect Effects 0.000 description 6
• 230000037387 scars Effects 0.000 description 6
• 230000002195 synergetic effect Effects 0.000 description 6
• 238000013519 translation Methods 0.000 description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
• 206010002091 Anaesthesia Diseases 0.000 description 5
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
• 108090000174 Interleukin-10 Proteins 0.000 description 5
• 230000000996 additive effect Effects 0.000 description 5
• 229940072056 alginate Drugs 0.000 description 5
• 125000000539 amino acid group Chemical group 0.000 description 5
• 230000037005 anaesthesia Effects 0.000 description 5
• 229940035674 anesthetics Drugs 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 230000002924 anti-infective effect Effects 0.000 description 5
• 238000004422 calculation algorithm Methods 0.000 description 5
• 229910052799 carbon Inorganic materials 0.000 description 5
• 239000001768 carboxy methyl cellulose Substances 0.000 description 5
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 238000001804 debridement Methods 0.000 description 5
• 239000003995 emulsifying agent Substances 0.000 description 5
• 239000000945 filler Substances 0.000 description 5
• 210000002683 foot Anatomy 0.000 description 5
• 239000003193 general anesthetic agent Substances 0.000 description 5
• 210000004394 hip joint Anatomy 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000002294 steroidal antiinflammatory agent Substances 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• 208000027502 Ankle fracture Diseases 0.000 description 4
• 108010069176 Connexin 30 Proteins 0.000 description 4
• 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 4
• 102100039401 Gap junction beta-6 protein Human genes 0.000 description 4
• 102100025623 Gap junction delta-2 protein Human genes 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 4
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 229940035676 analgesics Drugs 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• 210000001264 anterior cruciate ligament Anatomy 0.000 description 4
• 229940088710 antibiotic agent Drugs 0.000 description 4
• 229960005475 antiinfective agent Drugs 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000004888 barrier function Effects 0.000 description 4
• 239000012620 biological material Substances 0.000 description 4
• 230000001851 biosynthetic effect Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 108010015417 connexin 36 Proteins 0.000 description 4
• 108010015408 connexin 37 Proteins 0.000 description 4
• 239000008387 emulsifying waxe Substances 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 210000000416 exudates and transudate Anatomy 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 210000003128 head Anatomy 0.000 description 4
• 239000000416 hydrocolloid Substances 0.000 description 4
• 210000000281 joint capsule Anatomy 0.000 description 4
• 210000003041 ligament Anatomy 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000005265 lung cell Anatomy 0.000 description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
• 229920001778 nylon Polymers 0.000 description 4
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 239000012188 paraffin wax Substances 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 229920001983 poloxamer Polymers 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 206010039722 scoliosis Diseases 0.000 description 4
• 229910052709 silver Inorganic materials 0.000 description 4
• 239000004332 silver Substances 0.000 description 4
• 230000003637 steroidlike Effects 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000011200 topical administration Methods 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
• 241000567030 Ampulloclitocybe clavipes Species 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 206010006585 Bunion Diseases 0.000 description 3
• 229920000742 Cotton Polymers 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 206010020100 Hip fracture Diseases 0.000 description 3
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 3
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 102000029749 Microtubule Human genes 0.000 description 3
• 108091022875 Microtubule Proteins 0.000 description 3
• 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 239000004677 Nylon Substances 0.000 description 3
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 229920000297 Rayon Polymers 0.000 description 3
• 208000007103 Spondylolisthesis Diseases 0.000 description 3
• 206010043101 Talipes Diseases 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 210000003423 ankle Anatomy 0.000 description 3
• 230000000844 anti-bacterial effect Effects 0.000 description 3
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 3
• 229960000541 cetyl alcohol Drugs 0.000 description 3
• 238000004140 cleaning Methods 0.000 description 3
• 201000011228 clubfoot Diseases 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000001186 cumulative effect Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 229960005309 estradiol Drugs 0.000 description 3
• 229930182833 estradiol Natural products 0.000 description 3
• 210000003195 fascia Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000011540 hip replacement Methods 0.000 description 3
• 239000003326 hypnotic agent Substances 0.000 description 3
• 230000000147 hypnotic effect Effects 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000035992 intercellular communication Effects 0.000 description 3
• 229960002725 isoflurane Drugs 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 210000000629 knee joint Anatomy 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 239000006210 lotion Substances 0.000 description 3
• 210000004688 microtubule Anatomy 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 238000003032 molecular docking Methods 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 230000003204 osmotic effect Effects 0.000 description 3
• 239000005022 packaging material Substances 0.000 description 3
• 230000002980 postoperative effect Effects 0.000 description 3
• 239000002964 rayon Substances 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 210000004872 soft tissue Anatomy 0.000 description 3
• 238000007619 statistical method Methods 0.000 description 3
• 239000000021 stimulant Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000011477 surgical intervention Methods 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 238000011883 total knee arthroplasty Methods 0.000 description 3
• 238000002054 transplantation Methods 0.000 description 3
• 239000003357 wound healing promoting agent Substances 0.000 description 3
• VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 2
• 208000025978 Athletic injury Diseases 0.000 description 2
• 208000008035 Back Pain Diseases 0.000 description 2
• 108010081589 Becaplermin Proteins 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 206010007710 Cartilage injury Diseases 0.000 description 2
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
• 102000004237 Decorin Human genes 0.000 description 2
• 108090000738 Decorin Proteins 0.000 description 2
• 208000008960 Diabetic foot Diseases 0.000 description 2
• 208000001708 Dupuytren contracture Diseases 0.000 description 2
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• 208000004067 Flatfoot Diseases 0.000 description 2
• 206010061159 Foot deformity Diseases 0.000 description 2
• 206010016997 Forearm fracture Diseases 0.000 description 2
• 208000031220 Hemophilia Diseases 0.000 description 2
• 208000009292 Hemophilia A Diseases 0.000 description 2
• 208000007446 Hip Dislocation Diseases 0.000 description 2
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
• 208000004575 Infectious Arthritis Diseases 0.000 description 2
• 208000034693 Laceration Diseases 0.000 description 2
• 206010024453 Ligament sprain Diseases 0.000 description 2
• 206010055082 Lip injury Diseases 0.000 description 2
• 208000008930 Low Back Pain Diseases 0.000 description 2
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
• 108010025020 Nerve Growth Factor Proteins 0.000 description 2
• 206010031264 Osteonecrosis Diseases 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical group [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
• 102100035194 Placenta growth factor Human genes 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 229920002413 Polyhexanide Polymers 0.000 description 2
• 208000024288 Rotator Cuff injury Diseases 0.000 description 2
• 206010039227 Rotator cuff syndrome Diseases 0.000 description 2
• 208000007613 Shoulder Pain Diseases 0.000 description 2
• 229920002385 Sodium hyaluronate Polymers 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 206010041738 Sports injury Diseases 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 208000000491 Tendinopathy Diseases 0.000 description 2
• 206010043255 Tendonitis Diseases 0.000 description 2
• UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 2
• 102100035000 Thymosin beta-4 Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 241000469816 Varus Species 0.000 description 2
• 208000024248 Vascular System injury Diseases 0.000 description 2
• 208000012339 Vascular injury Diseases 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000004599 antimicrobial Substances 0.000 description 2
• 210000001188 articular cartilage Anatomy 0.000 description 2
• 210000000544 articulatio talocruralis Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 210000000845 cartilage Anatomy 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 229940082500 cetostearyl alcohol Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000003109 clavicle Anatomy 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 239000003405 delayed action preparation Substances 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 150000004141 diterpene derivatives Chemical class 0.000 description 2
• 235000013399 edible fruits Nutrition 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000004744 fabric Substances 0.000 description 2
• 208000020089 femoral neck fracture Diseases 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 210000001145 finger joint Anatomy 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 238000002683 hand surgery Methods 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000013150 knee replacement Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 230000005499 meniscus Effects 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 239000003973 paint Substances 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 210000004197 pelvis Anatomy 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 108010031345 placental alkaline phosphatase Proteins 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 229920001993 poloxamer 188 Polymers 0.000 description 2
• 229940044519 poloxamer 188 Drugs 0.000 description 2
• 229920000728 polyester Polymers 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 229920001296 polysiloxane Polymers 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 210000000513 rotator cuff Anatomy 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 201000001223 septic arthritis Diseases 0.000 description 2
• 210000000323 shoulder joint Anatomy 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000001509 sodium citrate Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 229940010747 sodium hyaluronate Drugs 0.000 description 2
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 201000004415 tendinitis Diseases 0.000 description 2
• OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
• 210000003813 thumb Anatomy 0.000 description 2
• 108010079996 thymosin beta(4) Proteins 0.000 description 2
• 230000008467 tissue growth Effects 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 238000003151 transfection method Methods 0.000 description 2
• 210000000623 ulna Anatomy 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 210000000707 wrist Anatomy 0.000 description 2
• PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
• OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
• BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
• BSWWXRFVMJHFBN-UHFFFAOYSA-N 2,4,6-tribromophenol Chemical compound OC1=C(Br)C=C(Br)C=C1Br BSWWXRFVMJHFBN-UHFFFAOYSA-N 0.000 description 1
• SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• 108091027075 5S-rRNA precursor Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000005606 Activins Human genes 0.000 description 1
• 108010059616 Activins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 241001474374 Blennius Species 0.000 description 1
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 108010076119 Caseins Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 208000025962 Crush injury Diseases 0.000 description 1
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
• NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102000006402 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Human genes 0.000 description 1
• 108010044063 Endocrine-Gland-Derived Vascular Endothelial Growth Factor Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000289669 Erinaceus europaeus Species 0.000 description 1
• 229940127406 Estrogen Receptor Agonists Drugs 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
• 101710082451 Gap junction beta-3 protein Proteins 0.000 description 1
• 102100039416 Gap junction beta-4 protein Human genes 0.000 description 1
• 101710129297 Gap junction delta-4 protein Proteins 0.000 description 1
• 102100025627 Gap junction delta-4 protein Human genes 0.000 description 1
• 102100039288 Gap junction gamma-2 protein Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
• 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
• 206010019909 Hernia Diseases 0.000 description 1
• 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
• 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
• 101000746084 Homo sapiens Gap junction gamma-2 protein Proteins 0.000 description 1
• 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000002746 Inhibins Human genes 0.000 description 1
• 108010004250 Inhibins Proteins 0.000 description 1
• 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
• 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 208000032984 Intraoperative Complications Diseases 0.000 description 1
• 208000005137 Joint instability Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• 102000010445 Lactoferrin Human genes 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 206010072970 Meniscus injury Diseases 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• 108090000742 Neurotrophin 3 Proteins 0.000 description 1
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034464 Periarthritis Diseases 0.000 description 1
• 208000006735 Periostitis Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 229920000081 Polyestradiol phosphate Polymers 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920000289 Polyquaternium Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 208000004550 Postoperative Pain Diseases 0.000 description 1
• 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 102400000827 Saposin-D Human genes 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 108050003978 Semaphorin Proteins 0.000 description 1
• 102000014105 Semaphorin Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000000875 Spinal Curvatures Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 208000021945 Tendon injury Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
• 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
• 206010044654 Trigger finger Diseases 0.000 description 1
• IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 239000000488 activin Substances 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
• 239000002597 adenosine A2 receptor agonist Substances 0.000 description 1
• 239000012790 adhesive layer Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 210000005068 bladder tissue Anatomy 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 229940112869 bone morphogenetic protein Drugs 0.000 description 1
• 239000000316 bone substitute Substances 0.000 description 1
• 108010046910 brain-derived growth factor Proteins 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000002390 cell membrane structure Anatomy 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000007765 cera alba Substances 0.000 description 1
• 239000007766 cera flava Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 210000004439 collateral ligament Anatomy 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 229940035811 conjugated estrogen Drugs 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108010005226 connexin 30.3 Proteins 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 229920006037 cross link polymer Polymers 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000006837 decompression Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 229940101829 dermasil Drugs 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
• 229960003839 dienestrol Drugs 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 229940008099 dimethicone Drugs 0.000 description 1
• 239000004205 dimethyl polysiloxane Substances 0.000 description 1
• 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 210000002310 elbow joint Anatomy 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 210000003560 epithelium corneal Anatomy 0.000 description 1
• 229960001348 estriol Drugs 0.000 description 1
• PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
• 229950008385 estrone sulphate Drugs 0.000 description 1
• 229960002568 ethinylestradiol Drugs 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 201000010603 frozen shoulder Diseases 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 108010044046 gap 27 peptide Proteins 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000003349 gelling agent Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 229940075529 glyceryl stearate Drugs 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• 238000011597 hartley guinea pig Methods 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 239000008309 hydrophilic cream Substances 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 238000002169 hydrotherapy Methods 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000000893 inhibin Substances 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 108010004788 integrin alphavbeta6 Proteins 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 230000008407 joint function Effects 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 235000019136 lipoic acid Nutrition 0.000 description 1
• 239000008308 lipophilic cream Substances 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000000713 mesentery Anatomy 0.000 description 1
• IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
• 229960001390 mestranol Drugs 0.000 description 1
• CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000004200 microcrystalline wax Substances 0.000 description 1
• 235000019808 microcrystalline wax Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 229940055577 oleyl alcohol Drugs 0.000 description 1
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 208000030346 palmar fibromatosis Diseases 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 210000004417 patella Anatomy 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 210000003460 periosteum Anatomy 0.000 description 1
• 210000001322 periplasm Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 125000005642 phosphothioate group Chemical group 0.000 description 1
• 238000000554 physical therapy Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000003075 phytoestrogen Substances 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
• 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
• 229960000502 poloxamer Drugs 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 229960001298 polyestradiol phosphate Drugs 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920006254 polymer film Polymers 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 230000017363 positive regulation of growth Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 102000005962 receptors Human genes 0.000 description 1
• 108020003175 receptors Proteins 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 239000012925 reference material Substances 0.000 description 1
• 230000014493 regulation of gene expression Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• RCTGMCJBQGBLKT-PAMTUDGESA-N scarlet red Chemical compound CC1=CC=CC=C1\N=N\C(C=C1C)=CC=C1\N=N\C1=C(O)C=CC2=CC=CC=C12 RCTGMCJBQGBLKT-PAMTUDGESA-N 0.000 description 1
• 229960005369 scarlet red Drugs 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000004904 shortening Methods 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 210000001738 temporomandibular joint Anatomy 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 229960002663 thioctic acid Drugs 0.000 description 1
• 210000004888 thoracic abdominal cavity Anatomy 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
• 239000000724 thymus hormone Substances 0.000 description 1
• 210000002303 tibia Anatomy 0.000 description 1
• WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
• 229960001023 tibolone Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000011240 wet gel Substances 0.000 description 1
• 229940038903 xenaderm Drugs 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1